Asset profile
SEFA-1024
Small molecule
Evidence outlook · lead readout
NCT05889156 · High Triglycerides
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05889156: The trial is randomized and blinded with a placebo comparator and measures triglyceride change, the standard disease-defining outcome for this condition, but no results are posted yet, so whether the drug lowered triglycerides is still unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.